19 citations
,
May 2012 in “The journal of investigative dermatology/Journal of investigative dermatology”
This study found that mice lacking the type 3 IP(3) receptor in their hair follicles experienced repetitive hairloss and regrowth, indicating disrupted hair-cycle regulation potentially linked to specific signaling pathways.
This study suggests that chemotherapy-induced anagen effluvium represents patterned hairloss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.
In this study, petroleum ether extracts of Phyllanthus niruri promoted hair regrowth in testosterone-induced alopecia in rats by inhibiting the 5α-reductase enzyme.
45 citations
,
March 2001 in “Journal of Investigative Dermatology”
This study identified a new cytokeratin, mK6irs, specifically expressed in the inner root sheath of mouse hair follicles, distinguishing it as a member of the type II cytokeratin family.
KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hairloss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.
Sugary beverages increase the risk of pattern hairloss in men by 57%, and type 2 diabetes is linked to female pattern hairloss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hairloss.
Hairloss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.
PP405 is a new hairloss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.